Strong Price Performance and Market Context
On 26 Feb 2026, Lupin Ltd. surged to Rs.2331.2, marking its highest price level in the past year. This milestone comes after a four-day consecutive gain, during which the stock appreciated by 4.7%. The day’s performance was in line with the Pharmaceuticals & Biotechnology sector, which also showed positive movement. Lupin’s share price currently trades comfortably above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained upward momentum.
In comparison, the Sensex opened 142.71 points higher and was trading at 82,443.84, up 0.2%. Although the benchmark index remains 4.51% below its own 52-week high of 86,159.02, Lupin’s outperformance is notable. The Sensex’s 50-day moving average is positioned above its 200-day moving average, indicating a generally positive medium-term trend, supported by gains in mega-cap stocks.
Impressive One-Year Returns and Relative Strength
Over the past year, Lupin Ltd. has delivered a total return of 22.60%, more than double the Sensex’s 10.54% gain over the same period. The stock’s 52-week low was Rs.1774, highlighting a significant appreciation of approximately 31.4% from that level. This strong relative performance reflects the company’s ability to generate consistent growth and maintain investor confidence.
Patience pays off here! This Micro Cap from Fertilizers sector has delivered steady gains quarter after quarter. Now proudly part of our Reliable Performers list.
- - New Reliable Performer
- - Steady quarterly gains
- - Fertilizers consistency
Robust Financial Metrics Underpinning the Rally
Lupin Ltd.’s financial health remains a key driver behind the stock’s upward trajectory. The company maintains a low average debt-to-equity ratio of 0.10 times, reflecting prudent capital management. Net sales have grown at a compounded annual rate of 11.42%, while operating profit margins stand at a healthy 33.60%, indicating operational efficiency and strong profitability.
Recent quarterly results have been positive for three consecutive quarters, with the latest half-yearly Return on Capital Employed (ROCE) reaching a peak of 22.22%. Profit Before Tax excluding other income (PBT less OI) for the most recent quarter was Rs.1,833.91 crore, representing a robust growth of 43.6% compared to the previous four-quarter average. Net sales for the quarter also hit a record Rs.7,167.52 crore, underscoring strong top-line momentum.
Valuation and Institutional Confidence
The company’s Return on Equity (ROE) stands at 22%, complemented by an attractive Price to Book Value ratio of 5.3. Despite these strong fundamentals, Lupin’s stock trades at a discount relative to its peers’ average historical valuations, suggesting potential value for investors seeking quality mid-cap exposure.
Institutional investors hold a significant 47.08% stake in Lupin Ltd., reflecting confidence from entities with extensive analytical resources. This level of institutional ownership often correlates with enhanced market stability and informed trading activity.
Market Recognition and Quality Scores
Lupin Ltd. is among the top 1% of companies rated by MarketsMojo across a universe of over 4,000 stocks. It holds a Mojo Score of 78.0 and a current Mojo Grade of Buy, upgraded from Strong Buy on 16 Feb 2026. The company ranks 12th among mid-cap stocks and 50th across the entire market, highlighting its strong standing within the Pharmaceuticals & Biotechnology sector and broader market.
Lupin Ltd. caught your attention? Explore our comprehensive research report with in-depth analysis of this mid-cap Pharmaceuticals & Biotechnology stock – fundamentals, valuations, financials, and technical outlook!
- - Comprehensive research report
- - In-depth mid-cap analysis
- - Valuation assessment included
Consistent Returns and Market Outperformance
Beyond the recent rally, Lupin Ltd. has demonstrated consistent returns over the last three years. The stock has outperformed the BSE500 index in each of the past three annual periods, reinforcing its status as a reliable growth stock within the mid-cap segment. Over the past year, profits have surged by 73.5%, resulting in a low PEG ratio of 0.3, which indicates that earnings growth is outpacing the stock price increase, a positive sign for valuation metrics.
This combination of steady earnings growth, strong profitability, and disciplined financial management has contributed to Lupin’s ability to reach new price highs while maintaining solid fundamentals.
Summary of Key Financial Highlights
To summarise, Lupin Ltd.’s recent achievement of a 52-week high at Rs.2331.2 is supported by:
- Four consecutive days of gains, with a 4.7% return over this period
- Net sales growth at an annual rate of 11.42%
- Operating profit margin of 33.60%
- Record quarterly net sales of Rs.7,167.52 crore
- Strong PBT growth of 43.6% excluding other income
- ROCE at 22.22% and ROE at 22%
- Low debt-to-equity ratio of 0.10 times
- Institutional holdings at 47.08%
- Mojo Score of 78.0 with a Buy grade
These factors collectively underpin the stock’s robust performance and its ability to sustain upward momentum in a competitive sector.
Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →
